About: Studies on hemostasis in COVID‐19 deserve careful reporting of the laboratory methods, their significance and their limitations

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Studies on hemostasis in COVID‐19 deserve careful reporting of the laboratory methods, their significance and their limitations Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Studies on hemostasis in COVID‐19 deserve careful reporting of the laboratory methods, their significance and their limitations
Creator	Bareille, Marion Douxfils, Jonathan Fontana, Pierre Gouin-Thibault, Isabelle Hardy, Michael Lecompte, Thomas Lessire, Sarah Mullier, François
source	Medline; PMC
abstract	We read with much interest the recent observational study of Nougier et al., which aimed at studying thrombin generation (TG) and fibrinolysis profiles of COVID‐19 patients admitted to an intensive care unit (ICU) or to an internal medicine ward and receiving various schemes of prophylactic heparin.[1] They reported that thrombin potential remained within normal range despite heparin and that fibrinolysis was decreased in relation with increased plasminogen activator inhibitor 1 (PAI‐1) and thrombin‐activatable fibrinolysis inhibitor (TAFI) antigen plasma levels. Using the rotational thromboelastometry (ROTEM) delta device with EXTEM reagents and the addition of 0.625µg/mL tPA (referred to as ‘TEM‐tPA’), they reported decreased clot lysis in COVID‐19 patients, which was more pronounced in patients who presented a thrombotic event, compared to event‐free patients.
has issue date	2020-08-13(xsd:dateTime)
bibo:doi	10.1111/jth.15061
bibo:pmid	32790951
has license	no-cc
sha1sum (hex)	f6e4b93c210cb95d933c44eab3ccbddbdceef365
schema:url	https://doi.org/10.1111/jth.15061
resource representing a document's title	Studies on hemostasis in COVID‐19 deserve careful reporting of the laboratory methods, their significance and their limitations
has PubMed Central identifier	PMC7436855
has PubMed identifier	32790951
schema:publication	J Thromb Haemost
resource representing a document's body	covid:f6e4b93c210cb95d933c44eab3ccbddbdceef365#body_text
is schema:about of	named entity 'ICU' named entity 'heparin' named entity 'UFH' named entity 'observational study' named entity 'UFH' named entity 'COVID-19' named entity 'plasma' named entity 'sodium citrate' named entity 'plasma' named entity 'Neuville-sur-Oise' named entity 'fibrinolysis' named entity 'thromboelastometry' named entity 'LMWH' named entity 'reagent' named entity 'platelets' named entity 'heparin' named entity 'heparin' named entity 'France' named entity 'UFH' named entity 'tPA' named entity 'tPA' named entity 'enoxaparin' named entity 'acute phase reactants' named entity 'thrombin' named entity 'Sanofi' named entity 'tissue factor' named entity 'heparin' named entity 'UFH' named entity 'heparin' named entity 'UFH' named entity 'exogenous' named entity 'aPTT' named entity 'Nougier' named entity 'factor VIII' named entity 'heparin' named entity 'normal range' named entity 'laboratory tests' named entity 'blood collection' named entity '0.98' named entity 'reagent' named entity 'laboratory tests' named entity 'hypercoagulability' named entity 'anticoagulant drugs' named entity 'dextran' named entity 'ICU' named entity 'heparin' named entity 'binding to plasma proteins' named entity 'intensive care unit' named entity 'fibrinolysis' named entity 'Fonds National de la Recherche Scientifique' named entity 'CAT' named entity 'COVID19' named entity 'PF4' named entity 'fibrinolysis' named entity 'blood collection' named entity 'COVID-19' named entity 'COVID-19' named entity 'normal range' named entity 'plasma levels' named entity 'thrombin-activatable fibrinolysis inhibitor' named entity 'Germany' named entity 'Heparin' named entity '0.98' named entity 'PAI-1' named entity 'centrifugation' named entity 'plasminogen' named entity 'Paris' named entity 'fibrinolysis' named entity 'dextran sulfate' named entity 'activated partial thromboplastin time' named entity 'heparin' named entity 'confidence interval' named entity 'biomed' named entity 'thrombin'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software